OTC Markets OTCPK - Delayed Quote USD

Kyowa Kirin Co., Ltd. (KYKOF)

15.80 +0.40 (+2.60%)

As of October 30 at 4:00:00 PM EDT. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

GlobeNewswire 19d ago

4151.T
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

Business Wire 21d ago

4151.T
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

Pharmaceutical Technology 1mo ago

GUD.TO

4151.T
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

Hospital Management 1mo ago

GUD.TO

4151.T
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Business Wire 1mo ago

GUD.TO

4151.T
Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)

GlobeNewswire 1mo ago

GUD.TO

4151.T
Is Kyowa Kirin (TSE:4151) A Bargain Following Its Share Price Pullback?

Simply Wall St. 1mo ago

4151.T
Tech, Oil Concerns Cramp Asian Stock Markets

PREMIUM
MT Newswires 1mo ago

^N225

CL=F

5801.T
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC

GlobeNewswire 1mo ago

BMRN

NVS

ASND
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

Benzinga 1mo ago

4503.T

SUNPHARMA.NS

TEVA
Mid-cap biotechs join Trump’s latest round of drug pricing deals

BioPharma Dive 2mo ago

TEVA

ALC

4503.T
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push

Pharmaceutical Technology 2mo ago

4503.T

4151.T

SUNPHARMA.NS

Performance Overview

Return	KYKOF	Nikkei 225 (^N225)
YTD	+5.72%	+25.31%
1-Year	-1.01%	+20.36%
3-Year	-0.27%	+97.44%

U.S. markets close in 4h 32m

Kyowa Kirin Co., Ltd. (KYKOF)

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)

Is Kyowa Kirin (TSE:4151) A Bargain Following Its Share Price Pullback?

Tech, Oil Concerns Cramp Asian Stock Markets

Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

Mid-cap biotechs join Trump’s latest round of drug pricing deals

Trump lines up MFN deals with nine mid-size pharmas on drug pricing push